ES2321038T3 - Peptidos y compuestos que se unen a un receptor. - Google Patents

Peptidos y compuestos que se unen a un receptor. Download PDF

Info

Publication number
ES2321038T3
ES2321038T3 ES97954363T ES97954363T ES2321038T3 ES 2321038 T3 ES2321038 T3 ES 2321038T3 ES 97954363 T ES97954363 T ES 97954363T ES 97954363 T ES97954363 T ES 97954363T ES 2321038 T3 ES2321038 T3 ES 2321038T3
Authority
ES
Spain
Prior art keywords
baselineskip
acid
peptide
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97954363T
Other languages
English (en)
Spanish (es)
Inventor
William J. Dower
Ronald W. Barrett
Steven E. Cwirla
Christian M. Gates
Peter J. Schatz
Palaniappan Balasubramanian
Christopher R. Wagstrom
Richard Wayne Hendren
Randolph B. Deprince
Surekha Podduturi
Qun Yin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25071323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2321038(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2321038T3 publication Critical patent/ES2321038T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES97954363T 1996-12-11 1997-12-09 Peptidos y compuestos que se unen a un receptor. Expired - Lifetime ES2321038T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US764640 1996-12-11
US08/764,640 US5869451A (en) 1995-06-07 1996-12-11 Peptides and compounds that bind to a receptor

Publications (1)

Publication Number Publication Date
ES2321038T3 true ES2321038T3 (es) 2009-06-01

Family

ID=25071323

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97954363T Expired - Lifetime ES2321038T3 (es) 1996-12-11 1997-12-09 Peptidos y compuestos que se unen a un receptor.

Country Status (24)

Country Link
US (2) US5869451A (enExample)
EP (3) EP2336165A1 (enExample)
JP (1) JP4128225B2 (enExample)
KR (3) KR100668546B1 (enExample)
CN (1) CN100379760C (enExample)
AR (2) AR010752A1 (enExample)
AT (1) ATE420893T1 (enExample)
AU (1) AU725731B2 (enExample)
BR (1) BRPI9713914B1 (enExample)
CA (1) CA2274149C (enExample)
CO (1) CO5080768A1 (enExample)
DE (1) DE69739219D1 (enExample)
ES (1) ES2321038T3 (enExample)
HR (1) HRP970683B1 (enExample)
MA (1) MA26454A1 (enExample)
PA (1) PA8442601A1 (enExample)
PE (1) PE27599A1 (enExample)
SV (1) SV1997000104A (enExample)
TN (1) TNSN97201A1 (enExample)
TR (2) TR200401638T2 (enExample)
TW (1) TW515804B (enExample)
UY (1) UY24805A1 (enExample)
WO (1) WO1998025965A2 (enExample)
ZA (1) ZA9711045B (enExample)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
AR003431A1 (es) * 1995-06-07 1998-08-05 Glaxo Group Ltd Peptidos compuestos que se ligan al receptor de trombopoietina.
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP1032388A4 (en) * 1997-10-31 2002-10-02 Smithkline Beecham Corp NEW METAL COMPLEXES
JP2001521896A (ja) 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
WO1999022732A1 (en) 1997-10-31 1999-05-14 Smithkline Beecham Corporation Novel metal complexes
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PL219605B1 (pl) * 1998-10-23 2015-06-30 Kirin Amgen Inc Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP1225901A2 (en) * 1999-09-21 2002-07-31 Emory University Uses and compositions for treating platelet-related disorders using anagrelide
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001036604A2 (en) 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2001259432B2 (en) * 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
DE60136656D1 (de) 2000-12-05 2009-01-02 Alexion Pharma Inc Rationell entworfene Antikörper
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
JP2004535166A (ja) 2001-03-22 2004-11-25 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
JP2005506047A (ja) 2001-03-27 2005-03-03 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー 膜貫通型セリンプロテアーゼ９をコード化する核酸分子、コード化されたポリペプチドおよびそれらに基づく方法
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2484676A1 (en) 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
WO2003097834A2 (en) 2002-05-17 2003-11-27 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
ES2254725T3 (es) * 2002-06-29 2006-06-16 Aquanova German Solubilisate Technologies (Agt) Gmbh Concentrados de isoflavonas y metodos para su preparacion.
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
JP4412173B2 (ja) 2002-08-14 2010-02-10 日産化学工業株式会社 トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
AU2003275077B2 (en) * 2002-09-18 2010-02-04 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
CA2515779A1 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive method and compositions related to proteasomal interference
SG160224A1 (en) * 2003-05-12 2010-04-29 Affymax Inc Novel peptides that bind to the erythropoietin receptor
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
CA2525399A1 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds
EA010099B1 (ru) * 2003-05-12 2008-06-30 Афимакс, Инк. Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения
KR100776961B1 (ko) * 2003-08-12 2007-11-28 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 수용체 아고니스트 작용을 가지는 화합물
PT1675606T (pt) * 2003-08-28 2017-05-22 Janssen Pharmaceuticals Inc Péptidos e compostos que se ligam a um receptor
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
ES2295961T3 (es) 2003-12-31 2008-04-16 F. Hoffmann-La Roche Ag Proceso para la sintesis peptidica utilizacndo una cantidad reducida de agente de desproteccion.
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
DE602005023714D1 (de) 2004-02-20 2010-11-04 Biosurface Eng Tech Inc Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2)
MX2007000216A (es) * 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
EP1797127B1 (en) 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
CA2587382A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
CA2588979C (en) 2004-12-08 2013-01-22 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
AU2005314788B2 (en) 2004-12-14 2011-09-22 Nissan Chemical Industries, Ltd. Amide compound and thrombopoietin receptor activator
US8258258B2 (en) 2005-03-10 2012-09-04 Biontech Ag Dimeric or multimeric microproteins
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EA200800109A1 (ru) * 2005-06-23 2008-06-30 Аплаген Гмбх Суправалентные соединения
NZ563202A (en) 2005-07-15 2011-02-25 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
EP1904488B1 (en) 2005-07-20 2013-03-06 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
KR101350099B1 (ko) 2005-11-07 2014-01-09 닛산 가가쿠 고교 가부시키 가이샤 하이드라지드 화합물 및 트롬보포이에틴 리셉터 활성화제
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
CA2635498A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
DK2005185T3 (da) 2006-03-22 2011-01-31 Viral Logic Systems Technology Corp Fremgangsmåde til identifikation af polypeptidtargets
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
JP2009537145A (ja) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
WO2007142308A1 (ja) 2006-06-07 2007-12-13 Nissan Chemical Industries, Ltd. 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2046350A4 (en) 2006-06-22 2011-09-14 Biosurface Eng Tech Inc COMPOSITION AND METHOD FOR DELIVERING AMPLIFIER / CO-ACTIVATOR OF BMP-2 TO ENHANCE OSTEOGENESIS
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
WO2008095004A2 (en) * 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8183342B2 (en) * 2007-11-06 2012-05-22 Case Western Reserve University Method of treating chemotherapy-induced thrombocytopenia
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
WO2010108153A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
EP2492262B1 (en) 2009-10-23 2016-04-20 Nissan Chemical Industries, Ltd. Fused heterocyclic compound and thrombopoietin receptor activator
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
MX360946B (es) 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US10538555B2 (en) 2014-09-11 2020-01-21 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
CN107001455B (zh) 2014-11-19 2022-03-01 皇家飞利浦有限公司 利用hnl的诊断方法
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
LT3458111T (lt) 2016-05-19 2021-05-25 Bristol-Myers Squibb Company Pet vizualizacijos imunomoduliatoriai
EP3535280B1 (en) 2016-11-07 2022-03-16 Bristol-Myers Squibb Company Immunomodulators
US11066445B2 (en) 2017-06-23 2021-07-20 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of PD-1
AU2018306329B8 (en) * 2017-07-26 2025-02-20 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂
KR20210141460A (ko) * 2019-01-25 2021-11-23 잔센파마슈티카엔.브이. 방사선 및/또는 방사선 모방체 치료와 함께 간 손상을 완화하고 간 비대, 재생 및 세포 생착을 촉진하는 방법
CN113660943A (zh) 2019-01-25 2021-11-16 詹森药业有限公司 增强对全身放射/化学暴露反应的对器官和血管损伤的保护、造血恢复以及存活的方法
MA54830A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Procédés d'atténuation des effets toxiques d'agents vésicants et de gaz caustiques
JP2023510737A (ja) 2020-01-06 2023-03-15 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
WO2021202501A1 (en) 2020-03-30 2021-10-07 Bristol-Myers Squibb Company Immunomodulators
JP2024536246A (ja) 2021-10-01 2024-10-04 ヤンセン ファーマシューティカ エヌ．ベー． 前駆細胞産生を増加させる方法
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (enExample) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) * 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
PT644771E (pt) * 1992-06-11 2002-12-31 Alkermes Inc Sistema de entrega da droga eritropoietina
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
EP0722331A4 (en) 1993-08-25 1997-10-01 Systemix Inc METHOD FOR PRODUCING A POPULATION OF HIGHLY ENRICHED HEMATOPOIETIC STEM CELLS
WO1995011922A1 (en) * 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
PL178384B1 (pl) * 1994-02-14 2000-04-28 Univ Washington Wydzielone białko, wydzielone cząsteczki polinukleotydowe, wektor ekspresji, hodowana komórka, kompozycja farmaceutyczna do stymulacji wytwarzania płytek krwi u ssaka, sposób wytwarzania białka homeopoezyjnego, sposób otrzymywania przeciwciał, sposób stymulacji i namnażania komórek
AU1843595A (en) * 1994-02-14 1995-08-29 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EP0668352A1 (en) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
RO115788B1 (ro) * 1994-03-31 2000-06-30 Amgen Inc. Polipeptidă mgdf, derivat de polipeptidă mgdf, polipeptidă mgdf mono-pegilată şi procedee de obţinere a acestora
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
AU4163196A (en) * 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
WO1996034016A1 (en) * 1995-04-26 1996-10-31 Kyowa Hakko Kogyo Co., Ltd. Novel polypeptides
AR003431A1 (es) * 1995-06-07 1998-08-05 Glaxo Group Ltd Peptidos compuestos que se ligan al receptor de trombopoietina.
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체

Also Published As

Publication number Publication date
AR010752A1 (es) 2000-07-12
CA2274149C (en) 2008-07-15
ZA9711045B (en) 1999-06-09
BRPI9713914B8 (enExample) 2021-05-25
JP2001505898A (ja) 2001-05-08
CO5080768A1 (es) 2001-09-25
TW515804B (en) 2003-01-01
AU5854798A (en) 1998-07-03
WO1998025965A3 (en) 1998-08-13
SV1997000104A (es) 1998-09-18
TNSN97201A1 (fr) 2005-03-15
KR20050042505A (ko) 2005-05-09
BRPI9713914B1 (pt) 2017-06-20
US5869451A (en) 1999-02-09
MA26454A1 (fr) 2004-12-20
AR062931A2 (es) 2008-12-17
KR20060025611A (ko) 2006-03-21
CN100379760C (zh) 2008-04-09
JP4128225B2 (ja) 2008-07-30
KR100679576B1 (ko) 2007-02-07
US6121238A (en) 2000-09-19
KR100625708B1 (ko) 2006-09-20
TR199901971T2 (xx) 1999-12-21
UY24805A1 (es) 2000-12-29
HRP970683A2 (en) 1998-10-31
TR200401638T2 (tr) 2004-11-22
AU725731B2 (en) 2000-10-19
EP2336165A1 (en) 2011-06-22
WO1998025965A2 (en) 1998-06-18
ATE420893T1 (de) 2009-01-15
CN1245504A (zh) 2000-02-23
EP2028191A1 (en) 2009-02-25
DE69739219D1 (de) 2009-03-05
KR100668546B1 (ko) 2007-01-16
EP0948539A2 (en) 1999-10-13
BR9713914A (pt) 2000-02-29
PA8442601A1 (es) 2000-05-24
KR20000069408A (ko) 2000-11-25
PE27599A1 (es) 1999-03-29
HRP970683B1 (en) 2002-10-31
EP0948539B1 (en) 2009-01-14
CA2274149A1 (en) 1998-06-18

Similar Documents

Publication Publication Date Title
ES2321038T3 (es) Peptidos y compuestos que se unen a un receptor.
ES2395413T3 (es) Péptidos que se unen al receptor de eritropoyetina
US6506362B1 (en) Labeled compounds that bind to a thrombopoietin receptor
ES2303338T3 (es) Peptidos y compuestos que se unen a un receptor de trombopoyetina.
AU2004270656B2 (en) Peptides and compounds that bind to thrombopoietin receptors
JP2009504650A (ja) Ｔｐｏ受容体と結合するペプチドの使用
CA2621857A1 (en) Peptides and compounds that bind to a receptor
MXPA99005365A (en) Peptides and compounds that bind to a receptor
HK1129686A (en) Peptides and compounds that bind to a receptor
HK1163698B (en) Peptides and compounds that bind to a receptor
HK1163698A (en) Peptides and compounds that bind to a receptor
HK1096873B (en) Peptides and compounds that bind to thrombopoietin receptors